Elsevier

The Lancet

Volume 344, Issue 8931, 29 October 1994, Pages 1182-1186
The Lancet

Articles
Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients

https://doi.org/10.1016/S0140-6736(94)90506-1Get rights and content

Abstract

Summary

Lipid-lowering therapy ameliorates coronary atherosclerosis in patients with raised concentrations of low-density-lipoprotein (LDL) cholesterol. We have investigated whether a similar benefit can be obtained in normocholesterolaemic patients. We studied 79 normocholesterolaemic patients with coronary heart disease (70 male, 9 female), mean age 58 years, all non-smokers, with mean total cholesterol concentration 5 5 mmol/L. All patients received diet therapy and were randomly assigned placebo (39) or active treatment (40) with pravastatin, nicotinic acid, cholestyramine, and gemfibrozil stepwise as needed to reach the specified goal (total cholesterol ≤4·1 mmol/L, ratio of LDL/high-density-lipoprotein [HDL] cholesterol ≤2·0). Coronary angiograms at baseline and after 2·5 years of treatment were analysed by computer-assisted quantitative techniques. There was no significant difference in coronary atherosclerosis during follow-up between the active treatment and placebo groups; the mean minimum diameter narrowed significantly but to the same extent in both groups (change baseline to 2·5 years 0·14 [SD 0·42] and 0·15 [0·41] mm, respectively, both p<0·001). Similarly, the change in percentage stenosis did not differ between the groups (2·1 [10·6] vs 2·4 [10·3]%). By multiple regression analysis, the adjusted difference between the groups was a 0·04 mm (95% CI - 0 04 to 0·12 mm) increase in minimum diameter and a 0% (-1·7 to 1·7) change in percentage stenosis. The groups differed significantly in plasma lipids (% change in active minus % change in placebo group: -28% total cholesterol, -41% LDL-cholesterol, 13% HDL-cholesterol, -26% triglycerides, -31% apolipoprotein B, all p<0 001).

Thus, intensive pharmacological treatment of normocholesterolaemic patients has significant effects on plasma lipid concentrations but no angiographically measurable benefit on the coronary arteries.

References (28)

  • Pd Richardson et al.

    Influence of plaque configuration and stress distribution on fissuring or coronary atherosclerotic plaques

    Lancet

    (1989)
  • G. Brown et al.

    Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

    N Engl J Med

    (1990)
  • Dh Blankenhorn et al.

    Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts

    JAMA

    (1987)
  • Cited by (177)

    • The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial

      2014, Atherosclerosis
      Citation Excerpt :

      Another study performed in Korea revealed that the beneficial effects of statin therapy in AMI seem to vanish when LDL cholesterol is below 2.72 mmol/L (105 mg/dL) [12], which is consistent with the pretreatment concentration in our study. Furthermore, the beneficial changes of cholesterol lowering on regression of coronary atherosclerosis demonstrated by angiography are also directly related to the pretreatment level of LDL cholesterol, with little benefit occurring in patients with low LDL cholesterol levels [13]. Together, these results suggest that the reduction in the rate of coronary events with statins is influenced by the pretreatment level of LDL cholesterol and the benefit of statin therapy could decline or even vanish when LDL cholesterol is below a certain level.

    • Nonpharmacologic Treatment of Dyslipidemia

      2009, Progress in Cardiovascular Diseases
      Citation Excerpt :

      This 5-year study in men with a history of MI demonstrated a 26% reduction in total mortality and a 36% reduction in ischemic heart disease mortality. There have also been 7 clinical trials of niacin which assessed vascular anatomical end points (coronary artery lesions in 6, carotid Intimal Media Thickness [IMT] in 1).290-298 Five of these showed mean regression of the lesion dimensions from baseline.293-298

    • Statins for all: The new premed?

      2009, British Journal of Anaesthesia
    View all citing articles on Scopus
    View full text